Breakthroughs in pancreatic cancer research, treatment spark excitement at ASCO

In this episode, Shikha Jain, MD, speaks with Revolution Medicines' Alan Sandler, MD, about groundbreaking advancements with daraxonrasib and how these findings will continue to impact metastatic pancreatic cancer.

Daraxonrasib (RMC-6236, Revolution Medicines) is an investigational, oral pan-RAS inhibitor in development for treatment of advanced solid tumors, including pancreatic ductal adenocarcinoma.

·       Why the RASolute 302 trial got a standing ovation at ASCO. 3:16

·       What do you think changed scientifically to make this particular drug and its results possible? 6:12

·       What does the multi-selective RAS inhibition of this drug mean, and how does it differ from other drugs? 10:23

·       How would you recommend navigating the early access program (EAP) for patients and physicians who want this drug now? 13:13

·       What excites you about the future of pancreatic cancer and RAS treatment? 14:18

·       How can you imagine when these drugs will get into the hands of patients if we see good results? 17:28

We'd love to hear from you! Send your comments/questions to Jain at oncologyoverdrive@healio.com. Follow Healio on X and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Jain on X: @ShikhaJainMD and on Instagram @shikhajainmd. Sandler can be reached via email at inquiries@revmed.com.

Reference:

·        Wolpin BM, et al. LBA5. Presented at: ASCO Annual Meeting; May 29-June 2, 2026; Chicago.

Jain and Sandler report no relevant financial disclosures.